Nath Madhu, Chandra Parijat, Halder Nabanita, Singh Baskar, Deorari Ashok Kumar, Kumar Atul, Azad Rajvardhan, Velpandian Thirumurthy
Dept. Of Ophthalmology, Dr. Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical sciences, New Delhi, India.
Dept. Of Ocular pharmacology, Dr. Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical sciences, New Delhi, India.
PLoS One. 2016 Dec 29;11(12):e0168809. doi: 10.1371/journal.pone.0168809. eCollection 2016.
Examining the Retinal Renin Angiotensin System (RRAS) in the ROP neonates and analyzing the possibility of modulating the RRAS to prevent the progression in Oxygen Induced Retinopathy (OIR) model.
Vitreous of ROP patients (n = 44, median age 5.5 months) was quantified for RRAS components, VEGF, HIF-1α and compared with age matched control. The involvement of RRAS in ROP was tested in the rat model of OIR and compared with normoxia. Expressions of RAS components, VEGF and HIF-1α in retina were analyzed using qPCR and retinal structure and function was also analyzed. Effect of Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) was evaluated and compared with Bevacizumab which served as a positive control. Drug penetration into retina was confirmed by liquid chromatography coupled ESI-tandem mass spectroscopy (LC-MS/MS).
Multifold increase in the expression of RAS components in human vitreous and rat retina showed their involvement in ROP. ERG & fundus studies in OIR revealed the altered function of retina and were successfully prevented by ARB (telmisartan), ACEI (lisinopril) and bevacizumab. Retinal analysis revealed the presence of ACEI and ARB in their therapeutic levels.
This study for the first time demonstrates the upregulated level of RAS components in human ROP vitreous and further that the pharmacological intervention in RRAS can functionally and structurally preserve retina against the progression of ROP in the OIR model.
检测早产儿视网膜病变(ROP)新生儿的视网膜肾素血管紧张素系统(RRAS),并分析调节RRAS以预防氧诱导性视网膜病变(OIR)模型进展的可能性。
对ROP患者(n = 44,中位年龄5.5个月)的玻璃体进行RRAS成分、血管内皮生长因子(VEGF)、低氧诱导因子-1α(HIF-1α)定量,并与年龄匹配的对照组进行比较。在OIR大鼠模型中检测RRAS在ROP中的作用,并与常氧组进行比较。采用定量聚合酶链反应(qPCR)分析视网膜中RAS成分、VEGF和HIF-1α的表达,并分析视网膜结构和功能。评估血管紧张素转换酶抑制剂(ACEI)和血管紧张素受体阻滞剂(ARB)的作用,并与作为阳性对照的贝伐单抗进行比较。通过液相色谱-电喷雾串联质谱(LC-MS/MS)确认药物在视网膜中的渗透情况。
人玻璃体和大鼠视网膜中RAS成分表达的成倍增加表明它们参与了ROP。OIR模型中的视网膜电图(ERG)和眼底研究显示视网膜功能改变,而ARB(替米沙坦)、ACEI(赖诺普利)和贝伐单抗成功预防了这种改变。视网膜分析显示ACEI和ARB处于治疗水平。
本研究首次证明人ROP玻璃体中RAS成分水平上调,进一步表明对RRAS的药物干预可在功能和结构上保护视网膜,防止OIR模型中ROP的进展。